Antibody named S309 from SARS patient shows promise against COVID-19
An antibody called S309, identified in a blood sample from a SARS patient, inhibits related coronaviruses, including SARS-CoV-2, researchers have found.
List view / Grid view
An antibody called S309, identified in a blood sample from a SARS patient, inhibits related coronaviruses, including SARS-CoV-2, researchers have found.
A detailed analysis of the body's immune response to COVID-19 has revealed that it can recognise SARS-CoV-2 in many ways, meaning vaccines can be used to stop the spread of the virus.
Researchers have found that antibodies produced in response to SARS and COVID-19 are cross-reactive, but not cross protective in cells and mice.
A new article has outlined the body's inflammatory response to COVID-19 infection, saying that lipid mediators derived from omega-3 fatty acids could prevent life-threatening inflammation.
Researchers are utilising computers to aid in their investigations into a COVID-19 treatment. Here, we highlight three studies using simulations, calculations and AI to identify a drug to combat the coronavirus.
A vaccine currently in Phase I clinical trials was effective at inducing immune responses against SARS-CoV-2 in mice and rhesus macaques.
In a new article, researchers highlight the need for treatments to combat the potentially lethal overreaction of the immune system in the progression of COVID-19.
Using mass spectrometry, researchers have shown how human cells are changed by infection from SARS-CoV-2, allowing the team to identify drug targets to prevent viral reproduction.
A group of researchers has found that SARS-CoV-2 may not spread by faecal-to-oral transmission, but is able to infect the gastrointestinal tract via the TMPRSS2 and TMPRSS4 enzymes.
Two antibodies named B38 and H4 could work as a COVID-19 therapeutic by neutralising the virus, say researchers in China.
Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.
Researchers in Boston have repurposed their lab into a centre to test samples for COVID-19, releasing a blueprint of how to do so for other labs in the US.
The COVID-19 Protein Portal, established by UKRI and Wellcome, will allow scientists in the UK to access protein reagents needed for research.
Learn how you could use high-content analysis for functional & phenotypic assays in your infectious disease research or drug discovery.
Russian researchers have created a process for the development of mouse models for use in pre-clinical studies of COVID-19 treatments and vaccines.